Post-antifungal effect of the combination of anidulafungin with amphotericin B and fluconazole against fluconazole-susceptible and -resistant
Anidulafungin
Combination regimen
Post-antifungal effect
Candida albicans
Journal
Current medical mycology
ISSN: 2423-3439
Titre abrégé: Curr Med Mycol
Pays: Iran
ID NLM: 101647935
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
07
03
2022
revised:
25
04
2022
accepted:
11
05
2022
entrez:
19
1
2023
pubmed:
20
1
2023
medline:
20
1
2023
Statut:
ppublish
Résumé
Invasive candidiasis is a life-threatening condition that kills a large number of immunocompromised patients each year worldwide. We used post-antifungal effect studies to analyze the activities of anidulafungin (AFG), as a clinically crucial antifungal drug, amphotericin B (AMB), and fluconazole (alone and in combinations) against FLC-susceptible and -resistant We tested the phenomenon of post antifungal effects of FLC, AMB, AFG, and combinations of FLC+AFG, AFG+AMB, and FLC+AMB against 17 The FLC had no detectable post-antifungal effect independent of antifungal concentration and resembled drug-free FLC (control). Significant variations in the post-antifungal effect were observed when all AMB and AFG were compared to FLC. The combination of AFG and AMB with FLC resulted in effective activity compared to FLC alone. Combination regimens were rated as indifferent in general. Interestingly, low dosages of the AFG displayed increasing fungistatic action as it approached a fungistatic endpoint against Our findings suggested that brief exposure to AFG, in combination with FLC and AMB, at low concentrations of the medicines utilized, could be effective in the evaluation and optimization of new dosage regimens to manage candidiasis. However, future studies will determine the clinical utility of our findings.
Sections du résumé
Background and Purpose
UNASSIGNED
Invasive candidiasis is a life-threatening condition that kills a large number of immunocompromised patients each year worldwide. We used post-antifungal effect studies to analyze the activities of anidulafungin (AFG), as a clinically crucial antifungal drug, amphotericin B (AMB), and fluconazole (alone and in combinations) against FLC-susceptible and -resistant
Materials and Methods
UNASSIGNED
We tested the phenomenon of post antifungal effects of FLC, AMB, AFG, and combinations of FLC+AFG, AFG+AMB, and FLC+AMB against 17
Results
UNASSIGNED
The FLC had no detectable post-antifungal effect independent of antifungal concentration and resembled drug-free FLC (control). Significant variations in the post-antifungal effect were observed when all AMB and AFG were compared to FLC. The combination of AFG and AMB with FLC resulted in effective activity compared to FLC alone. Combination regimens were rated as indifferent in general. Interestingly, low dosages of the AFG displayed increasing fungistatic action as it approached a fungistatic endpoint against
Conclusion
UNASSIGNED
Our findings suggested that brief exposure to AFG, in combination with FLC and AMB, at low concentrations of the medicines utilized, could be effective in the evaluation and optimization of new dosage regimens to manage candidiasis. However, future studies will determine the clinical utility of our findings.
Identifiants
pubmed: 36654787
doi: 10.18502/cmm.8.2.10327
pii: CMM-8-2
pmc: PMC9825794
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8-15Informations de copyright
Copyright: © 2021, Published by Mazandaran University of Medical Sciences on behalf of Iranian Society of Medical Mycology and Invasive Fungi Research Center.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests to express.
Références
Antimicrob Agents Chemother. 2000 Apr;44(4):1108-11
pubmed: 10722525
Clin Microbiol Rev. 2007 Jan;20(1):133-63
pubmed: 17223626
J Antimicrob Chemother. 2002 Feb;49(2):345-51
pubmed: 11815578
J Med Microbiol. 2015 Jan;64(Pt 1):74-83
pubmed: 25351710
Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S318-26
pubmed: 2184510
J Appl Oral Sci. 2015 Jul-Aug;23(4):412-8
pubmed: 26398514
Med Princ Pract. 2012;21(5):442-6
pubmed: 22678101
Mycoses. 2014 Sep;57(9):553-9
pubmed: 24655219
Int J Antimicrob Agents. 2006 Jun;27 Suppl 1:7-11
pubmed: 16701982
J Oral Pathol Med. 2001 Sep;30(8):481-8
pubmed: 11545239
J Antimicrob Chemother. 2013 Jul;68(7):1660-8
pubmed: 23543609
BMC Infect Dis. 2018 Jan 8;18(1):24
pubmed: 29310582
Antimicrob Agents Chemother. 2002 Dec;46(12):4016-8
pubmed: 12435715
J Clin Microbiol. 2011 Apr;49(4):1274-9
pubmed: 21289155
Rev Iberoam Micol. 2014 Jan-Mar;31(1):42-8
pubmed: 24270071
Med Oral Patol Oral Cir Bucal. 2011 Jan 01;16(1):e23-8
pubmed: 20711160
J Clin Microbiol. 2008 Nov;46(11):3585-90
pubmed: 18784314
Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S188-224
pubmed: 12975752
Antimicrob Agents Chemother. 2009 Aug;53(8):3347-52
pubmed: 19364856
Mycoses. 2019 Aug;62(8):692-697
pubmed: 31132175
Diagn Microbiol Infect Dis. 2002 May;43(1):13-7
pubmed: 12052624
PLoS One. 2015 Jul 13;10(7):e0132730
pubmed: 26168269
Mycoses. 2016 Feb;59(2):93-100
pubmed: 26648048
Mycoses. 2015 Sep;58(9):536-43
pubmed: 26201447